Combined Immunotherapies in Metastatic ER+ Breast Cancer

Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.

Trial Details

NCT ID
NCT04563507
Phase
PHASE2
Sponsor
Weill Medical College of Cornell University
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)
  • Letrozole 2.5Mg Tab
  • Palbociclib 125mg
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Female ≥ 18 years of age pre and post-menopausal
  • Metastatic disease (≤ 5 sites of measurable disease by RECIST)
  • Eligible for treatment with CDK4/6 + aromatase inhibitors
  • Premenopausal status is defined as either:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →